Schrödinger and Viva Biotech Announce Strategic Collaboration to Generate and Interrogate Structures for Unsolved Targets
Collaboration aims to enable discovery of first-in-class therapeutic candidates
Under the terms of the collaboration, Schrödinger will identify drug discovery targets for which there are currently no crystal structures in the public domain, including those that could lead to first-in-class therapeutic candidates for its internal pipeline.
“This is an exciting collaboration. We have identified numerous promising targets that are challenging to drug in part because they lack high-resolution crystal structures.
“This collaboration brings together two leaders in the field of structure-based drug discovery,” said
Schrödinger’s industry-leading computational platform to accelerate drug discovery and materials design is deployed by leading biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. In addition to this global business, Schrödinger is also applying its computational platform to a robust pipeline of drug discovery programs in collaboration with pharmaceutical companies and has co-founded leading biotech companies. In addition, Schrödinger is using its platform to advance a pipeline of internal, wholly-owned drug discovery programs. Schrödinger’s significant and ongoing investment in basic research continues to drive advances in its computational platform. Founded in 1990, Schrödinger has over 400 employees in its
Cautionary Note Regarding Forward-looking Statements of Schrödinger
This press release contains forward-looking statements of Schrödinger within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those regarding Schrödinger’s expectations about the speed and capacity of its computational platform, its ability to expand the reach of structure-based drug discovery, and its ability to leverage its advanced computational platform to potentially design novel therapeutic candidates. Statements including words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schrödinger’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to it and on assumptions it has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond Schrödinger’s control, including its ability to further develop its computational platform, its reliance upon third-party providers of cloud-based infrastructure to host its software solutions, its reliance upon its third-party drug discovery collaborators, the ability to retain and hire key personnel and the direct and indirect impacts of the ongoing COVID-19 pandemic on its business and other risks detailed under the caption "Risk Factors" and elsewhere in its
Tel: +86 (0)21 6089 3288 (
Tel: +1 630 432 3100 (US)
Fax: +86 (0)21 6089 3290
IR Email: firstname.lastname@example.org
Source: Schrödinger, Inc.